Effects of fidarestat, an aldose reductase inhibitor, on nerve conduction velocity and bladder function in streptozotocin-treated female rats

Elena G. Zotova, George J. Christ, Weixin Zhao, Moses T. Tar, Srini D. Kuppam, Joseph C. Arezzo

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The effects of fidarestat, an aldose reductase inhibitor (ARI), were assessed on nerve conduction velocity (NCV) in somatic nerves and on multiple measures of bladder function in rats made hyperglycemic with streptozotocin (STZ) and in age-matched controls. Nerve conduction velocity was recorded at baseline and at 10, 20, 30, and 50 days after confirmation of the STZ-induced hyperglycemia in all rats (N=47); bladder function was assessed in a representative subset of rats (N=20) at Day 50. Caudal NCV was markedly slowed by STZ, and this effect was significantly reversed by fidarestat. The initial deficit and treatment-related improvement were especially evident for responses driven by high-frequency repetitive stimulation. Of the 11 parameters of bladder activity assessed, four measures-bladder capacity, micturition volume, micturition frequency, and bladder weight-were significantly different in the control and STZ-treated groups. These deficits were not affected by fidarestat. At Day 50, the induced deficits in bladder function were highly correlated with caudal NCV (r values ranging from 0.70 to 0.96; P values ranging from .02 to <.0001). These results suggested that fidarestat improved the slowing of somatic nerve NCV in hyperglycemic rats, but it was not effective in reversing associated bladder dysfunction, in spite of the highly significant correlation between these two diabetes-induced deficits. Possible explanations for this dissociation are discussed.

Original languageEnglish (US)
Pages (from-to)187-195
Number of pages9
JournalJournal of Diabetes and its Complications
Volume21
Issue number3
DOIs
StatePublished - May 2007

Fingerprint

Aldehyde Reductase
Neural Conduction
Streptozocin
Urinary Bladder
Urination
fidarestat
Hyperglycemia
Weights and Measures

Keywords

  • Diabetic cystopathy
  • Diabetic peripheral neuropathy
  • Fidarestat
  • High-frequency repetitive stimulation
  • STZ-induced diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of fidarestat, an aldose reductase inhibitor, on nerve conduction velocity and bladder function in streptozotocin-treated female rats. / Zotova, Elena G.; Christ, George J.; Zhao, Weixin; Tar, Moses T.; Kuppam, Srini D.; Arezzo, Joseph C.

In: Journal of Diabetes and its Complications, Vol. 21, No. 3, 05.2007, p. 187-195.

Research output: Contribution to journalArticle

@article{36f7268362fc42718eb9574539f22d07,
title = "Effects of fidarestat, an aldose reductase inhibitor, on nerve conduction velocity and bladder function in streptozotocin-treated female rats",
abstract = "The effects of fidarestat, an aldose reductase inhibitor (ARI), were assessed on nerve conduction velocity (NCV) in somatic nerves and on multiple measures of bladder function in rats made hyperglycemic with streptozotocin (STZ) and in age-matched controls. Nerve conduction velocity was recorded at baseline and at 10, 20, 30, and 50 days after confirmation of the STZ-induced hyperglycemia in all rats (N=47); bladder function was assessed in a representative subset of rats (N=20) at Day 50. Caudal NCV was markedly slowed by STZ, and this effect was significantly reversed by fidarestat. The initial deficit and treatment-related improvement were especially evident for responses driven by high-frequency repetitive stimulation. Of the 11 parameters of bladder activity assessed, four measures-bladder capacity, micturition volume, micturition frequency, and bladder weight-were significantly different in the control and STZ-treated groups. These deficits were not affected by fidarestat. At Day 50, the induced deficits in bladder function were highly correlated with caudal NCV (r values ranging from 0.70 to 0.96; P values ranging from .02 to <.0001). These results suggested that fidarestat improved the slowing of somatic nerve NCV in hyperglycemic rats, but it was not effective in reversing associated bladder dysfunction, in spite of the highly significant correlation between these two diabetes-induced deficits. Possible explanations for this dissociation are discussed.",
keywords = "Diabetic cystopathy, Diabetic peripheral neuropathy, Fidarestat, High-frequency repetitive stimulation, STZ-induced diabetes",
author = "Zotova, {Elena G.} and Christ, {George J.} and Weixin Zhao and Tar, {Moses T.} and Kuppam, {Srini D.} and Arezzo, {Joseph C.}",
year = "2007",
month = "5",
doi = "10.1016/j.jdiacomp.2005.10.001",
language = "English (US)",
volume = "21",
pages = "187--195",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Effects of fidarestat, an aldose reductase inhibitor, on nerve conduction velocity and bladder function in streptozotocin-treated female rats

AU - Zotova, Elena G.

AU - Christ, George J.

AU - Zhao, Weixin

AU - Tar, Moses T.

AU - Kuppam, Srini D.

AU - Arezzo, Joseph C.

PY - 2007/5

Y1 - 2007/5

N2 - The effects of fidarestat, an aldose reductase inhibitor (ARI), were assessed on nerve conduction velocity (NCV) in somatic nerves and on multiple measures of bladder function in rats made hyperglycemic with streptozotocin (STZ) and in age-matched controls. Nerve conduction velocity was recorded at baseline and at 10, 20, 30, and 50 days after confirmation of the STZ-induced hyperglycemia in all rats (N=47); bladder function was assessed in a representative subset of rats (N=20) at Day 50. Caudal NCV was markedly slowed by STZ, and this effect was significantly reversed by fidarestat. The initial deficit and treatment-related improvement were especially evident for responses driven by high-frequency repetitive stimulation. Of the 11 parameters of bladder activity assessed, four measures-bladder capacity, micturition volume, micturition frequency, and bladder weight-were significantly different in the control and STZ-treated groups. These deficits were not affected by fidarestat. At Day 50, the induced deficits in bladder function were highly correlated with caudal NCV (r values ranging from 0.70 to 0.96; P values ranging from .02 to <.0001). These results suggested that fidarestat improved the slowing of somatic nerve NCV in hyperglycemic rats, but it was not effective in reversing associated bladder dysfunction, in spite of the highly significant correlation between these two diabetes-induced deficits. Possible explanations for this dissociation are discussed.

AB - The effects of fidarestat, an aldose reductase inhibitor (ARI), were assessed on nerve conduction velocity (NCV) in somatic nerves and on multiple measures of bladder function in rats made hyperglycemic with streptozotocin (STZ) and in age-matched controls. Nerve conduction velocity was recorded at baseline and at 10, 20, 30, and 50 days after confirmation of the STZ-induced hyperglycemia in all rats (N=47); bladder function was assessed in a representative subset of rats (N=20) at Day 50. Caudal NCV was markedly slowed by STZ, and this effect was significantly reversed by fidarestat. The initial deficit and treatment-related improvement were especially evident for responses driven by high-frequency repetitive stimulation. Of the 11 parameters of bladder activity assessed, four measures-bladder capacity, micturition volume, micturition frequency, and bladder weight-were significantly different in the control and STZ-treated groups. These deficits were not affected by fidarestat. At Day 50, the induced deficits in bladder function were highly correlated with caudal NCV (r values ranging from 0.70 to 0.96; P values ranging from .02 to <.0001). These results suggested that fidarestat improved the slowing of somatic nerve NCV in hyperglycemic rats, but it was not effective in reversing associated bladder dysfunction, in spite of the highly significant correlation between these two diabetes-induced deficits. Possible explanations for this dissociation are discussed.

KW - Diabetic cystopathy

KW - Diabetic peripheral neuropathy

KW - Fidarestat

KW - High-frequency repetitive stimulation

KW - STZ-induced diabetes

UR - http://www.scopus.com/inward/record.url?scp=34247595874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247595874&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2005.10.001

DO - 10.1016/j.jdiacomp.2005.10.001

M3 - Article

C2 - 17493553

AN - SCOPUS:34247595874

VL - 21

SP - 187

EP - 195

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 3

ER -